Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TSRO

Tesaro (TSRO) Stock Price, News & Analysis

Tesaro logo

About Tesaro Stock (NASDAQ:TSRO)

Advanced Chart

Key Stats

Today's Range
$74.94
$74.97
50-Day Range
N/A
52-Week Range
$23.41
$75.16
Volume
1.19 million shs
Average Volume
1.97 million shs
Market Capitalization
$4.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive TSRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tesaro and its competitors with MarketBeat's FREE daily newsletter.

TSRO Stock News Headlines

Hedge Fund - Ivory Capital (Investment Mgmt)
Biopharma Cred. Regulatory News
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.
Gilbert H Kliman's Net Worth
Keval Desai's Net Worth
See More Headlines

TSRO Stock Analysis - Frequently Asked Questions

Tesaro, Inc. (NASDAQ:TSRO) posted its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing the consensus estimate of ($2.66) by $0.38. The company's revenue was up 94.2% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tesaro investors own include NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Netflix (NFLX), Meta Platforms (META), Alibaba Group (BABA) and AutoZone (AZO).

Company Calendar

Last Earnings
8/02/2018
Today
5/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:TSRO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-496,120,000.00
Net Margins
-295.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$223.33 million
Price / Cash Flow
N/A
Book Value
$4.58 per share
Price / Book
16.37

Miscellaneous

Free Float
N/A
Market Cap
$4.13 billion
Optionable
Optionable
Beta
0.38
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:TSRO) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners